1481 (1481) Fair Value & Analysis

Industrials · Market cap HK$1.6B

1 1481 1481 · HK

PriceHK$1.61

Fair ValueHK$0.1700

Upside-89.4%

Quality64/100

Evidence: Medium Range HK$0.1300 – HK$0.2100

Fair value as of: Jul 2, 2026

From 23 valuation models · updated today

Share price −8.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.4750 – HK$3.07 · fair‑value band HK$0.1300 – HK$0.2100 · the HK$1.61 price screens above the HK$0.1700 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1481 (1481) currently trades at HK$1.61, while our model-based Fair Value estimate is HK$0.1700 — implying the stock looks roughly 89.4% overvalued today. We read business quality at 64/100 (solid quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 1481 generated revenue of HK$205M at a net margin of 3.9%. Revenue grew 52.6% year over year. It earns a return on equity of 10.5%. The balance sheet holds a net cash position of HK$67.0M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$205M

Revenue growth (YoY) +52.6%

Net margin 3.9%

Return on equity 10.5%

Free cash flow HK$11.0M FY2025

P/E ratio 161.0

More key figures

Operating margin 3.7%

EPS (TTM) HK$0.0100

EPS growth (YoY) -63.5%

Net cash HK$67.0M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1481 reported revenue of HK$205M in FY2025 versus HK$168M in FY2021, a compound +5.1%/yr. Reported net income was HK$7.9M in FY2025, compounding +47.9%/yr from FY2021.

Revenue +5.1%/yr

FY21 HK$168M

FY22 HK$132M

FY23 HK$97.2M

FY24 HK$118M

FY25 HK$205M

Net income +47.9%/yr

FY21 HK$1.6M

FY22 −HK$16.5M

FY23 −HK$3.7M

FY24 −HK$12.0M

FY25 HK$7.9M

Is 1481 fairly valued? → Check now

Similar stocks

6 more Specialty Business Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Cintas Corporation CTAS	$180.40	$74.70	-59%
RELX PLC R1EL34	R$39.80	R$4.72	-88%
Thomson Reuters Corporation TRI	C$114.51	C$85.90	-25%
Copart, Inc CPRT	$29.48	$34.05	+16%
Global Payments Inc GPN	$62.47	$51.51	-18%
UL Solutions Inc ULS	$97.38	$29.61	-70%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1481 (1481) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.1700 versus a price of HK$1.61 — about −89% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1481?

Our model-based fair value for 1481 is HK$0.1700 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.61.

What is the quality score of 1481?

1481 has a Quality Score of 64/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1481 (1481)?

1481 reported trailing-twelve-month revenue of about HK$205M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1481?

The net profit margin of 1481 is about 3.9%, meaning it keeps roughly 3.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.